Letters Data openness

Independent public inquiries needed to ensure drug safety

BMJ 2010; 341 doi: http://dx.doi.org/10.1136/bmj.c6336 (Published 16 November 2010) Cite this as: BMJ 2010;341:c6336
  1. Brian Edwards, pharmacovigilance consultant1
  1. 1Ashtead, Surrey KT21 1PX, UK
  1. brian.edwards47{at}btinternet.com

Cohen’s article on rosiglitazone asks whether regulators, industry, and the clinical community will do a better job next time.1 What is the evidence that “anything” went wrong or “anyone” did anything wrong? How can a drug safety regulator allege that a drug may have caused thousands of excess deaths …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial